OncLive® and the Ruesch Center for the Cure of Gastrointestinal Cancers Name Winners of the 2023 Luminary Awards in GI Cancers
October 11, 2023 10:55 ET
|
OncLive®
CRANBURY, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- OncLive, the nation’s leading multimedia resource for oncology professionals, and The Ruesch Center for the Cure of Gastrointestinal (GI) Cancers,...
OncLive and the Ruesch Center for the Cure of Gastrointestinal Cancers Name Winners of the 2022 Luminary Awards in Gastrointestinal Cancers
November 09, 2022 09:00 ET
|
OncLive®
CRANBURY, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- OncLive®, the nation’s leading multimedia resource for oncology professionals, and The Ruesch Center for the Cure of Gastrointestinal (GI) Cancers,...
Rhizen Pharmaceuticals S.A. announces poster presentation of RP4010, a calcium release-activated calcium (CRAC) channel inhibitor in preclinical models of Gastrointestinal (GI) Cancers at the 2019 AACR Annual Meeting
March 26, 2019 07:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, March 26, 2019 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces poster presentation of RP4010, a novel first-in-class CRAC channel inhibitor in preclinical...